Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Trust Co. of Oklahoma

Trust Co. of Oklahoma cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 37.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 4,815 shares of the medical research company’s stock after selling 2,840 shares during the period. Trust Co. of Oklahoma’s holdings in Edwards Lifesciences were worth $356,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in EW. AE Wealth Management LLC raised its position in shares of Edwards Lifesciences by 14.8% in the 2nd quarter. AE Wealth Management LLC now owns 4,618 shares of the medical research company’s stock worth $427,000 after buying an additional 594 shares during the period. ProShare Advisors LLC raised its holdings in shares of Edwards Lifesciences by 7.2% in the 2nd quarter. ProShare Advisors LLC now owns 88,565 shares of the medical research company’s stock worth $8,181,000 after purchasing an additional 5,944 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Edwards Lifesciences by 42.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 932 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 280 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Edwards Lifesciences by 73.6% during the 2nd quarter. Public Sector Pension Investment Board now owns 23,267 shares of the medical research company’s stock worth $2,149,000 after purchasing an additional 9,863 shares during the period. Finally, Bank of Montreal Can raised its holdings in Edwards Lifesciences by 1.7% in the second quarter. Bank of Montreal Can now owns 1,227,199 shares of the medical research company’s stock valued at $112,706,000 after buying an additional 20,240 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research reports. Barclays raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. Royal Bank of Canada increased their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Evercore ISI decreased their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Trading Down 1.4 %

Edwards Lifesciences stock opened at $68.99 on Thursday. The firm has a 50-day moving average price of $72.25 and a two-hundred day moving average price of $70.86. The firm has a market capitalization of $40.69 billion, a price-to-earnings ratio of 9.96, a PEG ratio of 3.59 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 EPS. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.